After the revolution? Ethical and social challenges in 'personalized genomic medicine'

Personalized Medicine

Volumn 9, Issue 4, 2012, Pages 429-439

  Juengst, Eric T ^a   Settersten, Richard A ^b   Fishman, Jennifer R ^c   McGowan, Michelle L ^d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

empowerment; participatory; personalization; prediction; prevention; social worlds; stakeholders

Indexed keywords

ETHICS; GENOMICS; HEALTH CARE POLICY; HEALTH PROMOTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SOCIAL ASPECT;

EID: 84862747248     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.12.37     Document Type: Review

References (83)

1. Collins F. The Language of Life: DNA and the Revolution in Personalized Medicine. HarperCollins, NY, USA (2010).
2. Xu L, Zheng H, Sedmak D et al. The re-emerging concept of personalized healthcare. Per. Med. 5(5), 457-469 (2008).
3. Guyer M, Collins F. The human genome project and the future of medicine. Am. J. Dis. Child. 147, 1145-1152 (1993).
4. Zerhouni E. The NIH roadmap. Science 302(5642), 63-72 (2003).
5. Khoury M, Gwinn M, Burke W et al. Will genomics widen or help heal the schism between medicine and public health? Am. J. Prevent. Med. 33(4), 310-317 (2007).
6. Collins F, Green E, Guttmacher A et al. A vision for the future of genomics research. Nature 422(6934), 835-847 (2003).
7. Hunter D, Khoury M, Drazen J. Letting the genome out of the bottle - will we get our wish? N. Engl. J. Med. 358(2), 105-107 (2008).
8. Janssens A, Gwinn M, Bradley L et al. A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am. J. Hum. Genet. 82(3), 593-599 (2008).
9. Offit K. Genomic profiles for disease risk. JAMA 299(11), 1353-1355 (2008).
10. Guttmacher A, Collins F, Carmona R. The family history - more important than ever. N. Engl. J. Med. 351(22), 2333-2336 (2004).
11. Kaput J. Nutrigenomics research for personalized nutrition and medicine. Curr. Opin. Biotechnol. 19(2), 110-120 (2008).
12. Nicholson J, Holmes E, Wilson I. Gut microorganisms, mammalian metabolism and personalized health care. Nat. Rev. Micro. 3(5), 431-438 (2005).
13. Curtin C. First steps for personalized medicine. Genome Technol. 40-45 (2008).
14. Hudson K. The health benefits of genomics: out with the old, in with the new. Health Affairs 27(6), 1612-1615 (2008).
15. Taylor P. When consent gets in the way. Nature 456, 32-33 (2008).
16. Burke W, Kuszler P, Starks H et al. Translational genomics: seeking a shared vision of benefit. Am. J. Bioethics 8(3), 54-56 (2008).
17. Maienschein J, Sunderland M, Ankeny R et al. The ethos and ethics of translational research. Am. J. Bioethics 8(3), 43-51 (2008).
18. Burke W, Psaty B. Personalized medicine in the era of genomics. JAMA 298, 1682-1684 (2007).
19. Hudson K, Javitt G, Burke W et al. ASHG statement on direct-to-consumer genetic testing in the United States. Am. J. Hum. Genet. 81, 635-637 (2007).
20. Mcinerney J. Implications of DTC genetic test services for providers. Presented at: Fourth Meeting of the CEERS Investigators. National Human Genome Research Institute, MD, USA, 4 March 2008.
21. Magnus D, Cho M, Cook-Deegan R. Direct-to-consumer genetic tests: beyond medical regulation? Genome Med. 1(2), 17 (2009).
22. McGowan M, Fishman J, Lambrix M. Prescribing risk assessment: clinicians and the promise of personalized medicine. Presented at: Society of Social Studies of Science. Cleveland City Center Hotel, OH, USA, 2-5 November 2011.
23. Hedgecoe A. The politics of personalised medicine - pharmacogenetics in the clinic. Cambridge University Press, Cambridge, UK (2004).
24. Kahn J. How a drug becomes "ethnic": law, commerce, and the production of racial categories in medicine. Yale J. Health Policy Law Ethics 4(1), 1-46 (2004).
25. Rothstein M, Epps P. Science and society: ethical and legal implications of pharmacogenomics. Nat. Rev. Genet. 2, 228-231 (2001).
26. Smart A, Martin P, Parker M. Tailored medicine: whom will it fit? The ethics of patient and disease stratification. Bioethics 18(4), 322-343 (2004).
27. Avard D, Knoppers B. Genomic medicine: considerations for health professionals and the public. Genome Med. 1(2), 25 (2009).
28. Rhodes R. Rethinking research ethics. Am. J. Bioethics 5(1), 7-28 (2005).
29. McGowan M, Fishman J, Lambrix M. Personal genomics and individual identities: motivations and moral imperatives of early users. N. Genet. Soc. 29(3), 261-290 (2010).
30. Murphy S, Churchill S, Bry L et al. Instrumenting the health care enterprise for discovery research in the genomic era. Genome Res. 19(9), 1675-1681 (2009).
31. Powell K, Christianson C, Cogswell W et al. Educational needs of primary care physicians regarding direct-to-consumer genetic testing. J. Genet. Counsel. 21(3), 469-478 (2011).
32. Lock M, Freeman J, Chilibeck G et al. Susceptibility genes and the question of embodied identity. Med. Anthropol. Q. 21(3), 256-276 (2007). Through a qualitative study of family members of patients with Alzheimer's disease, the authors argue that the uncertainty of predictive genomic risk assessment is likely to complicate the notion of conceptualizing people as 'genetically at risk' for complex diseases.
33. Clarke A, Shim J, Mamo L et al. Biomedicalization: technoscientific transformations of health, illness, and U.S. biomedicine. Am. Sociol. Rev. 68(2), 161-194 (2003).
34. Post S. Preventing schizophrenia and Alzheimer disease: comparative ethics. Schizophrenia Res. 51(1), 103-108 (2001).
35. Whitehouse P, Juengst E. Antiaging medicine and mild cognitive impairment: practice and policy issues for geriatrics. J. Am. Geriatr. Soc. 53(8), 1417-1422 (2005).
36. Kaye C, Laxova R, Livingston J et al. Integrating genetic services into public health: guidance for state and territorial programs from the National Newborn Screening and Genetics Resource Center. Commun. Genet. 4(3), 175-196 (2001).
37. Juengst E. Population genetic research and screening: conceptual and ethical issues. In: The Oxford Handbook of Bioethics. Steinbock B (Ed.). Oxford University Press, Oxford, UK 471-490 (2006). Juengst argues that conflating phenotypic and genotypic prevention may pose threats to individuals' reproductive autonomy, and that promoters of genomic medicine should be careful to avoid treading into the territory of genotypic prevention.
38. Cowan RS. Moving up the slippery slope: mandated genetic screening on Cyprus. Am. J. Med. Genet. C Semin. Med. Genet. 151C(1), 95-103 (2009).
39. Harmon A. Couples cull embryos to halt heritage of cancer; The DNA age: choosing genes. The New York Times, 3 September (2006).
40. McDougall G, Rosamond M. Personalized medicine: what it means for patient centered healthcare and how to address its current challenges. PWC View 13, 1-8 (2010).
41. Nordgren A, Juengst E. Can genomics tell me who I am? Wssentialistic rhetoric in direct-to-consumer DNA testing. N. Genet. Soc. 28(2), 157-172 (2009). Nordgren and Juengst argue that there are dangers in the essentialist rhetoric used by consumer genomics companies to appeal for consumers.
42. Juengst E. FACE facts: why human genetics will always provoke bioethics. J. Law Med. Ethics 32(2), 267-275 (2004).
43. Lee S. Pharmacogenomics and the challenge of health disparities. Public Health Genomics 12(3), 170-179 (2009).
44. Kohane I. The twin questions of personalized medicine: who are you and whom do you most resemble? Genome Med. 1(1), 1-3 (2009). Kohane argues that effective applications of personalized medicine require both robust understanding of individual patients and the subpopulations to which they belong.
45. Ioannidis J. Expectations, validity, and reality in omics. J. Clin. Epidemiol. 63(9), 945-949 (2010).
46. Trusheim M, Berndt E, Douglas F. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 6(4), 287-293 (2007).
47. Tayo B, Teil M, Tong L et al. Genetic background of patients from a University Medical Center in Manhattan: implications for personalized medicine. PLoS ONE 6(5), e19166 (2011).
48. Reardon J. Democratic mis-haps: the problem of democratization in a time of biopolitics. BioSocieties 2, 239-256 (2007).
49. Kahn J. Race, pharmacogenomics, and marketing: putting BiDil in context. Am. J. Bioethics 6(5), W1-W5 (2006).
50. Lee SS, Crawley L. Research 2.0: social networking and direct-to-consumer (DTC) genomics. Am. J. Bioethics 9(6-7), 35-44 (2009).
51. Swan M. Emerging patient-driven health care models: an examination of health social networks, consumer personalized medicine and quantified self-tracking. Int. J. Environ. Res. Publich Health 6(2), 492-525 (2009).
52. Kieffer C. Citizen empowerment a developmental perspective. In: Studies in Empowerment: Steps Towards Understanding and Action. Rappaport J, Swift C, Hess R (Eds). The Haworth Press, NY, USA, 9-36 (1984).
53. Raman S, Tutton R. Life, science, and biopower. Sci. Technol. Hum. Values 35(5), 711-734 (2010).
54. Novas C, Rose N. Genetic risk and the birth of the somatic individual. Economy Soc. 29(4), 485-513 (2000).
55. Prainsack B, Reardon J, Hindmarsh R et al. Personal genomes: misdirected precaution. Nature 456(7218), 34-35 (2008).
56. McGowan M, Fishman J. Using lessons learned from BRCA testing and marketing: what lies ahead for whole genome scanning services. Am. J. Bioeth. 8(6), 18-20 (2008).
57. Harvey A. Genetic risks and healthy choices: creating citizen-consumers of genetic services through empowerment and facilitation. Sociol. Health Illness 32(3), 365-381 (2010). Harvey applies Foucauldian theory to argue that the patient empowerment rhetoric used in genomic risk assessment for disease prevention requires active collaboration by patient consumers to promote individual health. She argues that in the contemporary political economy the 'good citizen' is one who is a responsible healthcare consumer.
58. Herzlich C, Pierret J. Illness and self in society. Johns Hopkins University Press, MD, USA (1987).
59. Gieryn T. Boundary-work and the demarcation of science from non-science: strains and interests in professional ideologies of scientists. Am. Sociol. Rev. 48(6), 781-795 (1983).
60. Clarke A. A social worlds research adventure: the case of reproductive science. In: Theories of Science in Society. Cozzens S, Gieryn T (Eds). Indiana University Press, IN, USA, 23-50 (1990).
61. Clarke A, Star S. The social worlds/arenas framework as a theory-methods package. In: Handbook of Science and Technology Studies. Hackett E, Amsterdamska O, Lynch M, Wacjman J (Eds). MIT Press, Cambridge, MA, USA, 113-137 (2007). Clarke and Star describe the epistemology of social worlds/arenas framework and the methodological approach it entails.
62. Strauss A. A social world perspective. In: Studies in Symbolic Interaction (Volume 1). Denzin N (Ed.). JAI Press, CT, USA, 119-128 (1978).
63. Strauss A, Corbin J. Basics of qualitative research: Grounded theory procedures and techniques. SAGE Publications, CA, USA (1990).
64. Personalized Medicine Coalition: the case for personalized medicine (2009). www.personalizedmedicinecoalition.org
65. US Department of Health and Human Services. Personalized health care: opportunities, pathways, resource (2007). www.hhs.gov/myhealthcare/news/phc- report.pdf
66. US Department of Health and Human Services. Personalized health care: pioneers, partnerships, progress (2008). www.hhs.gov/myhealthcare/news/phc-2008- report.pdf
67. NIH. NIH roadmap for medical research (2009). http://nihroadmap.nih.gov
68. Obama B. Genomics and personalized medicine act of 2006. www.govtrack.us/congress/bills/109/s3822/text
69. 23andMe. Find out if your child may be at risk for 24 inherited conditions (2011). www.23andme.com/health/carrier
70. The Ohio State University. Personalized health care: the key to meaningful healthcare reform (2011). http://phc.osumc.edu/tag/ personalizedhealth-care
71. Huang A. Genetic and public policy center. Who regulates genetic tests? (2009). www.dnapolicy.org/policy.issue.php?action=detail&issuebrief-id=10
72. Genetic information nondiscrimination act of 2008. www.genome.gov/ 24519851
73. Aristotle's ethics. http://plato.stanford.edu/entries/aristotleethics
74. P4 Medicine Institute. Healthcare of the future - P4 medicine (2011). http://p4mi.org/sites/p4mi.direct2care.com/files/whitepapers/1/Fact-Sheet-P4MI2. pdf
75. The President's Council on bioethics: the changing moral focus of newborn screening. (2008). http://bioethics.georgetown.edu/pcbe/reports/newborn- screening/Newborn%20Screening%20for%20the%20web.pdf
76. Strategic Medicine. Stratified medicine (2012). www.strategicmedicine. com/index.php/stratified-medicine
77. 23andMe. 23andMe core values (2008). www.23andme.com/about/values
78. deCODEme complete genetic scan (2009). www.decodeme.com/complete-genetic- scan
79. Knome. www.knome.com
80. Mygenome. www.mygenome.com/pages/1/index.htm
81. Navigenics (2009). www.navigenics.com/visitor/about-us/collaborators
82. Cleveland Clinic. About the Center for Personalized Medicine (2011). my.clevelandclinic.org/cph/about-us/mission.aspx
83. Duke Personalized Medicine. What is personalized medicine? (2011). www.dukepersonalizedmedicine.org/what-is-personalized-medicine